Table 4.

Clinical monitoring and evidence-based management of common PegIFN-α adverse reactions.

Adverse reaction	Baseline assessment	On-treatment monitoring	Management strategies	Key references
Hematological Toxicity	Complete blood count (CBC) with differential.	• CBC q2–4wk for first 12–24 wk, then q4–12wk if stable.	• Neutropenia (e.g., ANC <0.75–1.0 × 109/L): Reduce PegIFN dose per guideline. Consider G-CSF for profound/symptomatic cases. • Thrombocytopenia (e.g., platelets <50–70 × 109/L): Dose reduction. Discontinue if platelets <25–50 × 109/L or with active bleeding. • Note: Lymphopenia is managed supportively (infection prophylaxis) and is not a primary trigger for dose adjustment.	(14, 16, 17, 25, 43, 63, 64)
Thyroid Dysfunction	TSH, free T4; consider anti-TPO antibodies.	TSH and free T4 q12wk. Monitor for symptoms.	• Hypothyroidism: Initiate levothyroxine. PegIFN typically continues. • Hyperthyroidism: Symptomatic management; initiate anti-thyroid drugs if indicated. Discontinue PegIFN for severe/refractory symptoms or thyroid storm.	(20, 21, 25, 63, 64)
Neuropsychiatric Effects	Detailed psychiatric history.	• Educate patient/family. • Use validated tools (e.g., PHQ-9) at each visit.	• Mild-moderate symptoms: Supportive care ± pharmacotherapy (e.g., SSRIs). Continue with close monitoring. • Severe depression, suicidal ideation, psychosis, or mania: Immediate psychiatric consultation. Interrupt or permanently discontinue PegIFN.	(19, 25, 63, 64)
Ocular Toxicity (Vascular)	Fundoscopic exam for high-risk patients (hypertension, diabetes, pre-existing retinopathy).	• Educate to report visual symptoms immediately. • Consider periodic screening in high-risk patients. • Prompt ophthalmology referral for symptomatic patients.	• Asymptomatic, non–vision-threatening retinopathy (e.g., cotton-wool spots): May continue therapy with education/monitoring. • Symptomatic or vision-threatening findings (e.g., retinal hemorrhage): Permanently discontinue PegIFN.	(25, 27, 30, 63, 64)
Hepatotoxicity (ALT/AST Flare)	Liver function tests (LFTs); baseline HBV DNA.	• ALT/AST q4wk initially, then q8–12wk. • Critical: Monitor HBV DNA (e.g., q4–12wk) to differentiate flare etiology.	• Immune-mediated flare (ALT rise with declining/stable HBV DNA): Represents on-therapy immune activity. Usually continue with closer monitoring. • Virological breakthrough (ALT rise with rising HBV DNA): Indicates treatment failure. Adjust NA therapy; consider discontinuing PegIFN. • Severe hepatitis (ALT >10x ULN, jaundice, decompensation): Discontinue PegIFN.	(25, 63–66)
Pulmonary Toxicity (e.g., PAH)	Cardiopulmonary symptom review; assess PAH risk factors.	• Educate to report new/worsening dyspnea, chest pain, syncope, or exercise intolerance. • For symptomatic patients: Prompt evaluation with NT-proBNP and echocardiography. Specialist referral if suspected.	Confirmed PegIFN-associated pulmonary arterial hypertension mandates permanent discontinuation. Initiate PAH-specific therapy under specialist guidance.	(25, 63, 64, 68–70, 73)
Cardiovascular Toxicity	Detailed cardiovascular history, symptom review, risk assessment; baseline ECG.	Inquire about palpitations, chest pain, edema, or undue fatigue at each visit. Evaluate symptomatic patients with ECG, troponin, and echocardiography as indicated.	• Symptomatic arrhythmia, myopericarditis: Interrupt therapy for cardiology consultation. Permanent discontinuation is often required. • Asymptomatic dysfunction: Individualized risk-benefit assessment.	(25, 63, 64, 74–76, 81)
Renal Toxicity	Serum creatinine, eGFR, urinalysis with microscopy.	Monitor serum creatinine and urinalysis q12wk. Nephrology consult for unexplained creatinine rise (>30% from baseline) or new/worsening proteinuria/hematuria.	• New-onset/worsening proteinuria, hematuria, or acute kidney injury: Interrupt PegIFN and evaluate. Most toxicities are reversible upon withdrawal. • Confirmed PegIFN-induced glomerulopathy (e.g., collapsing FSGS, TMA): Permanently discontinue and manage under nephrology care.	(25, 63, 64, 83–85, 89)
Dermatological & Musculoskeletal	History of psoriasis, chronic rash, severe myalgia/arthritis.	Regularly inquire about and examine for rash, alopecia, joint pain, or muscle weakness.	• Mild rash/alopecia: Supportive care; therapy usually continues. • Severe/generalized dermatitis (e.g., psoriasis exacerbation), suspected immune-mediated myositis/arthritis: Interrupt therapy for specialist evaluation. Dose reduction or discontinuation may be necessary.	(25, 57–60, 63, 64)

This monitoring and management framework translates the mechanistic insights of systemic immune activation detailed in Section 3 into clinical practice. All recommendations are consistent with and contextualized within the principles of current international guidelines (25, 63, 64). Dose reduction and discontinuation criteria are formulation-specific. Clinical management must adhere to the latest product prescribing information and clinical practice guidelines (65, 66). Illustrative examples include: for PegIFN-α-2a, reduction from 180 µg to 135 µg weekly; for PegIFN-α-2b, reduction from 1.5 µg/kg to 1.0 µg/kg weekly. These examples are for illustration only. All decisions should be individualized based on toxicity severity, trajectory, and the specific clinical context.

ALT, alanine aminotransferase; ANC, absolute neutrophil count; anti-TPO, anti-thyroid peroxidase antibody; AST, aspartate aminotransferase; CBC, complete blood count; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; G-CSF, granulocyte colony-stimulating factor; HBV, hepatitis B virus; LFTs, liver function tests; NA, nucleos(t)ide analogue; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAH, pulmonary arterial hypertension; PegIFN, pegylated interferon; PHQ-9, Patient Health Questionnaire-9; qXwk, every X weeks (e.g., q4wk = every 4 weeks); SSRI, selective serotonin reuptake inhibitor; TMA, thrombotic microangiopathy; TSH, thyroid-stimulating hormone; ULN, upper limit of normal.